CASI Pharmaceuticals
CASI
CASI was delisted on the 25th of February, 2026.
30 hedge funds and large institutions have $3.21M invested in CASI Pharmaceuticals in 2015 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 2 closing their positions.
6% less funds holding
Funds holding: 32 → 30 (-2)
17% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 6
20% less capital invested
Capital invested by funds: $4.03M → $3.21M (-$822K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WSCM
Wellington Shields Capital Management
New York
|
+$31.5K |
| 2 |
Renaissance Technologies
New York
|
+$8.82K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$4.32K |
| 4 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$2.38K |
| 5 |
AIG
American International Group
New York
|
+$142 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$1.11M |
| 2 |
MC
Moors & Cabot
Boston,
Massachusetts
|
-$13.8K |
| 3 |
EEG
E.E. Geduld
|
-$13K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$7.04K |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$3.37K |
CASI Hedge Fund Activity: Q1 2015 in Review
30 of the 3,770 institutional investors tracked by Wall St. Rank reported a position in CASI Pharmaceuticals (CASI) for Q1 2015, worth a combined $3.21M — down 20% from $4.03M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of CASI and 0 opened new positions — a net loss of 2 holders — while 6 trimmed existing stakes and 5 added.
The largest buyer was Wellington Shields Capital Management, adding an estimated $31.5K. The largest seller was Sabby Management, exiting entirely with an estimated $1.11M sold.
- 30 institutional investors held CASI Pharmaceuticals (CASI) as of Q1 2015, down from 32 in Q4 2014.
- Funds reported $3.21M of CASI Pharmaceuticals stock for Q1 2015, down 20% quarter-over-quarter.
- 0 funds opened new CASI Pharmaceuticals positions in Q1 2015 and 2 closed out, a net change of -2 holders.
- The largest CASI Pharmaceuticals buyer in Q1 2015 was Wellington Shields Capital Management, an estimated $31.5K added.
- The largest CASI Pharmaceuticals seller in Q1 2015 was Sabby Management, an estimated $1.11M sold.
Based on aggregated 13F filings for Q1 2015.